Latest Technology News

Aura Consolidated Group Inc. is set to acquire Qoria Limited in a landmark $3 billion merger, creating a global leader in digital safety solutions with a new ASX listing under the ticker AXQ.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

EV Resources has launched its first-ever diamond drilling program at the Los Lirios Antimony Project in Mexico, aiming to unlock the potential of a historically high-grade mineral system. The company is also refining assay methods to ensure accurate measurement of antimony content.

Corporate Travel Management's founder Jamie Pherous retires, handing over leadership to Ana Pedersen as the company navigates accounting challenges and aims to relist on the ASX.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.

Pivotal Metals has revealed ore sorting test results at its Horden Lake project that deliver up to a 2.1 times uplift in copper grade, promising substantial cost savings and flexible development options in Quebec’s Tier 1 mining jurisdiction.

Cluey Ltd has terminated its planned acquisition of Education Futures Group, the parent of Art of Smart, citing unmet conditions. The company remains focused on expanding its blended learning offerings and exploring new acquisition opportunities.

Imagion Biosystems has submitted its Investigational New Drug application to the U.S. FDA for its MagSense® HER2 Imaging Agent, marking a pivotal step toward launching a Phase 2 clinical trial for breast cancer detection.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Recce Pharmaceuticals has secured a second Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to test its RECCE 327 Gel in burn wound infection models, underscoring growing military interest in its synthetic anti-infectives.